In the HER2‐negative cohort, 46% of the cancers were ER‐positive/progesterone receptor (PgR)‐positive, 7% were ER‐positive/PgR‐negative, 5% were ER‐negative/PgR‐positive, and 42% were ER‐negative/PgR‐negative. Here, ERBB2 is linked to cancer.